Daraxonrasib Nearly Doubles Survival in Pancreatic Cancer: What Nurses Need to Know

The landscape of pancreatic cancer treatment is undergoing a significant shift following results from a landmark phase 3 clinical trial of daraxonrasib. Lead investigators at Memorial Sloan Kettering Cancer Center (MSK) report that this targeted therapy nearly doubled median overall survival for patients with metastatic disease compared to standard chemotherapy. For the oncology nursing community, these results represent more than just statistics; they signal a new era of precision prophylaxis and clinical possibility.

A new standard for KRAS mutations

Daraxonrasib works by specifically targeting mutations in the RAS gene, particularly the KRAS family, which drives over 90% of pancreatic cancer cases. While these mutations were once considered undruggable, this new molecule effectively shuts down the signals that cause uncontrolled tumor growth.

Mary Larsen, MSN, RN, OCN, a clinical trials nurse at MSK who has been on the front lines of these investigations, emphasizes the broad reach of this advancement. According to Larsen, who sat down for an interview with Oncology Nursing News, "It's another treatment option for almost everyone because almost everyone has a KRAS mutation with pancreas cancer."

Clinical outcomes and survival data

The international phase 3 trial included patients previously treated for metastatic pancreatic cancer. The data revealed a median overall survival of 13.2 months for those receiving daraxonrasib, compared to 6.7 months for the chemotherapy group. Progression-free survival also doubled, reaching 7.2 months for the targeted therapy group.

Larsen notes that these impressive figures were derived from a specific patient population, which leaves room for future growth. She explains that "that doubling of the median overall survival, that was only looking at the second line of treatment."

Consequently, the potential for daraxonrasib in earlier stages of care remains an area of active investigation.

The nursing perspective: Quality of life and side effects

For oncology nurses, managing the toxicity profiles of new agents is a primary concern. While chemotherapy often results in serious nausea and weight loss, daraxonrasib is generally better tolerated. Only 1.2% of patients in the daraxonrasib group discontinued treatment due to side effects, compared to 11.2% in the chemotherapy arm.

However, the drug is not without challenges. A common side effect is a skin rash that can become inflamed or sore. MSK nursing teams work closely with dermatology services to manage these symptoms with topical treatments. Despite these hurdles, the sense of optimism in the clinic is palpable.

"We're still learning a lot," Larsen said of the ongoing research. "I think that's part of the hope too, that we actually are still learning. So far the results have given us a lot of hope and excitement, but the thought that maybe we could even get more, better data still is exciting too."

Future frontiers

As the FDA moves toward potential approval following its breakthrough therapy designation, MSK researchers are exploring daraxonrasib in combination with immunotherapy and antibody-drug conjugates. For now, the focus remains on the immediate impact on patient lives. As Larsen suggested, the current data are just the beginning of what may be achieved in targeting the drivers of this aggressive disease.